Conecte-se

Bibliografias temáticas / Omeprazole / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Omeprazole.

Artigos de revistas sobre o tema "Omeprazole"

Autor: Grafiati

Publicado: 4 de junho de 2021

Última modificação: 9 de março de 2023

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Omeprazole".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Sartika, Eria, Eko Suhartono e Agung Biworo. "PENGARUH LANSOPRAZOL DAN OMEPRAZOL TERHADAP AKTIVITAS ENZIM KATALASE HEPAR TIKUS". Berkala Kedokteran 12, n.º 2 (7 de outubro de 2016): 255. http://dx.doi.org/10.20527/jbk.v12i2.1875.

Texto completo da fonte

Resumo:

Abstract: Lansoprazole and omeprazole is a Proton Pump Inhibitor class of drugs that are often used for the treatment of peptic ulcers. Lansoprazole and omeprazole have an influence on the various target organs exposed. Mechanism of lansoprazole and omeprazole in influencing the activity of the enzyme catalase is competing with absolute catalase enzyme substrate (H2O2) in the binding of the enzyme active site. This study aims to determine the effect of lansoprazole and omeprazole against liver catalase enzyme activity. This study was a laboratory experimental study conducted in three groups, namely the control group (P0), the treatment group (P1) is given lansoprazole 30 mg and a treatment group (P2) given omeprazole 20 mg. The result showed the value of Km of the control group (P0) of 13.482 mmol/dm3, the treatment group (P1) of 11,227 mmol/dm3 and the treatment group (P2) of 6,327 mmol/dm3. Analysis of statistical data shows the regression correlation value of p for P1 was 0,01 adn for P2 was 0,02 (p <0.05) and the R value approaching 1 with a linear graph Lineweaver Burk meaningful. Concluded that lansoprazole and omeprazole may affect the activity of the liver enzyme catalase. Keywords: lansoprazole, omeprazole, enzyme catalase, rat liver Abstrak: Lansoprazol dan omeprazol merupakan obat golongan proton pump inhibitor yang sering digunakan untuk pengobatan tukak lambung. Lansoprazol dan omeprazol memiliki berbagai pengaruh terhadap organ target yang terpajan. Mekanisme lansoprazol dan omeprazol dalam mempengaruhi aktivitas enzim katalase adalah berkompetisi dengan substrat absolut enzim katalase (H2O2) dalam mengikat sisi aktif enzim. Penelitian ini bertujuan untuk mengetahui pengaruh lansoprazol dan omeprazol terhadap aktivitas enzim katalase hepar. Penelitian ini merupakan penelitian quasi eksperimental yang dilakukan pada 3 kelompok, yakni kelompok kontrol (P0), kelompok perlakuan (P1) diberikan lansoprazol 30 mg dan kelompok perlakuan (P2) diberikan omeprazol 20 mg. Hasil penelitian didapatkan nilai Km pada kelompok kontrol (P0) sebesar 13,482 mmol/dm3, pada kelompok perlakuan (P1) sebesar 11,227mmol/dm3 dan pada kelompok perlakuan (P2) sebesar 6,327mmol/dm3. Analisis data statistik korelasi regresi menunjukkan nilai p pada P1 0,01 dan pada P2 0,02 (p<0,05) serta nilai R mendekati 1 dengan grafik linear Lineweaver Burk yang menanjak. Disimpulkan bahwa lansoprazol dan omeprazol dapat mempengaruhi aktivitas enzim katalase hepar mencit. Kata-kata kunci: lansoprazol, omeprazol, enzim katalase, hepar mencit

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Fienda, Adrully El, e Ainun Wulandari. "Analisis Efektivitas Biaya Penggunaan Omeprazol dan Pantoprazol dalam Terapi Peptic Ulcer pada Pasien Lansia Rawat Inap di Rumah Sakit Umum Adhyaksa". Jurnal Farmasi Higea 14, n.º 2 (30 de dezembro de 2022): 169. http://dx.doi.org/10.52689/higea.v14i2.475.

Texto completo da fonte

Resumo:

PPI (proton pump inhibitors) adalah salah satu obat yang umum diresepkan pada gangguan lambung. Penelitian ini bertujuan untuk mengetahui nilai efektivitas biaya pada penggunaan Omeprazol dan Pantoprazol pada pasien rawat inap di RSU Adhyaksa. Penelitian ini menggunakan metode deskriptif kuantitatif dengan pengambilan data secara retrospektif dengan membandingkan Direct Medical Cost (biaya medik langsung). Subjek dari penelitian ini adalah semua pasien rawat inap di RSU Adhyaksa yang mendapatkan terapi Omeprazol dan Pantoprazol dengan usia >50 tahun dalam periode Januari 2020 – Mei 2022. Hasil efektivitas terapi dapat dilihat dari data rekam medis pasien dan biaya pengobatan pasien yang dianalisis dengan perhitungan rasio rerata efektivitas biaya (ACER). Berdasarkan efektivitas terapi pantoprazol (95,2%) lebih efektif dibandingkan omeprazol (90,5%). Terdapat perbedaan nilai ACER pada pasien yang menggunakan pantoprazole sebesar Rp 1.802.501,- dan pada omeprazole sebesar Rp 2.022.952,-. ICER pada penelitian ini menunjukkan angka Rp. 601.510,-. Pada penelitian ini terdapat perbedaan efektivitas antara pantoprazol dan omeprazole sebagai terapi Peptik ulser. Biaya terapi peptic ulser pada pantoprazol lebih rendah dibandingkan omeprazole.

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Hutahaean, Amsaline, Gayatri Citraningtyas e Defny S. Wewengkang. "ANALISIS EFEKTIVITAS BIAYA PADA PASIEN GASTRITIS RAWAT INAP DI RUMAH SAKIT BHAYANGKARA MANADO". PHARMACON 8, n.º 4 (28 de novembro de 2019): 767. http://dx.doi.org/10.35799/pha.8.2019.29351.

Texto completo da fonte

Resumo:

ABSTRACTGastritis is an inflammatory process in the gastric mucosa and submucosa or health problems caused by irritation and infection factors. Treatment therapy used in gastritis is the proton pump inhibitor (PPI), H2 receptor antagonists, and antacids. Giving treatment therapy used by patients has an impact on the amount of medical expenses. The purpose of this study was to determine a more cost effective therapy between the use of omeprazole and lansoprazole in hospitalized gastrtitis patients at Bhayangkara Hospital, Manado. The method used in this study is Cost Effectiveness Analysis with a retrospective data collection on the period of January - December 2018. The sample in this study was 44 patients, consisting of 25 patients using with omeprazole therapy and 19 patients with lansoprazole therapy. The results showed that the most cost-effective PPI was omeprazole with an ACER value of IDR 643,210.37 and ICER value of IDR 631,023.17/ day for each increase in effectiveness if there is a transfer from lansoprazole to omeprazole Keywords: Cost Effectiveness Analysis, Gastritis, Omeprazole, Lansoprazol. ABSTRAKGastritis adalah proses inflamasi pada mukosa dan submukosa lambung atau gangguan kesehatan yang disebabkan oleh faktor iritasi dan infeksi. Terapi pengobatan yang digunakan pada penyakit gastritis yaitu proton pump inhibitor (PPI), antagonis reseptor H2, serta antasida. Pemberian terapi pengobatan yang digunakan oleh pasien berdampak pada besarnya biaya pengobatan. Tujuan penelitian ini untuk menentukan terapi yang lebih cost effective antara penggunaan omeprazol dan lansoprazol pada pasien gastrtitis rawat inap di RS Bhayangkaara Manado. Metode yang digunakan pada penelitian ini adalah Cost-Effectiveness Analysis dengan rancangan pengambilan data secara retrospektif pada periode Januari – Desember 2018. Sampel pada penelitian ini sebanyak 44 pasien, terdiri dari 25 pasien pengguna terapi omeprazol dan 19 pasien pengguna terapi lansoprazol. Hasil penelitian menunjukkan terapi PPI yang lebih cost-effective adalah omeprazol dengan nilai ACER sebesar Rp. 643.210,37 dan nilai ICER sebesar Rp. 631.023,17/hari untuk setiap peningkatan efektivitas jika akan dilakukan perpindahan dari lansoprazol ke omeprazol. Kata Kunci : Analisis Efektivitas Biaya, Gastritis, Omeprazol, Lansoprazol.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Nasrullah, Mohammed Z., Khalid Eljaaly, Thikryat Neamatallah, Usama A. Fahmy, Abdulmohsin J. Alamoudi, Hussain T. Bakhsh e Ashraf B. Abdel-Naim. "Omeprazole Prevents Colistin-Induced Nephrotoxicity in Rats: Emphasis on Oxidative Stress, Inflammation, Apoptosis and Colistin Accumulation in Kidneys". Pharmaceuticals 15, n.º 7 (23 de junho de 2022): 782. http://dx.doi.org/10.3390/ph15070782.

Texto completo da fonte

Resumo:

The clinical value of colistin, a polymyxin antibiotic, is limited by its nephrotoxicity. Omeprazole is a commonly prescribed proton pump inhibitor. The current study aimed to evaluate the effects of the concomitant administration of omeprazole on colistin-induced nephrotoxicity in rats. Omeprazole significantly ameliorated colistin nephrotoxicity as evidenced by prevention in the rise in the serum level of creatinine, urea and cystactin C as well as urinary N-acetylglucosamine activity. This was confirmed by histological studies that indicated a decreased incidence of interstitial nephritis, degenerative cortical changes and collagen deposition. This was accompanied by the prevention of oxidative stress as omeprazole significantly inhibited the lipid peroxidation, glutathione depletion and enzymatic exhaustion of superoxide dismutase as well as catalase. Additionally, omeprazole inhibited the expression of interleukin-6 and tumor necrosis factor-α. Further, omeprazole inhibited the colistin-induced rise in Bax and the down-regulation of Bcl2 mRNA expression. An assessment of the serum levels of colistin revealed that omeprazole had no significant impact. However, it was observed that omeprazole significantly inhibited the accumulation of colistin in kidney tissues. In conclusion, omeprazole protects against colistin-induced nephrotoxicity. This can be attributed to, at least partly, omeprazole’s anti-oxidant, anti-inflammatory and anti-apoptotic activities in addition to its ability to prevent the toxic accumulation of colistin in kidneys.

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

&NA;. "Omeprazole see Furosemide/omeprazole". Reactions Weekly &NA;, n.º 354 (junho de 1991): 11. http://dx.doi.org/10.2165/00128415-199103540-00049.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Javed, Mamoona, Muhammad Hayder Ali, Muhammad Saad Tanveer e Muhammad Hassan Tanveer. "Omeprazole vs Lansoprazole in the Management of Gastroesophageal Reflux Disease: A Systematic Literature Review". Journal of Medical Research and Innovation 4, n.º 2 (29 de março de 2020): e000204. http://dx.doi.org/10.32892/jmri.204.

Texto completo da fonte

Resumo:

Objective: To evaluate the effectiveness and safety of omeprazole compared to lansoprazole in Gastroesophageal reflux disease patients (GERD). Methods: A systematic search of MEDLINE, EMBASE (inception to December 2019) and CENTRAL (January 2011 to December 2019) was conducted to identify the relevant articles. A detailed inclusion-exclusion criterion was developed and implemented to screen the abstracts. Full texts of the selected abstracts were then assessed to establish their inclusion or exclusion in our review. Cochrane risk of bias criterion was used to assess the methodological quality of the included studies. All relevant data were extracted and the results were summarised narratively. Results: 9 studies met our inclusion-exclusion criteria and were included in this review. In all three trials reporting on heartburn and regurgitation, both omeprazole and lansoprazole were found to be effective in relieving the symptoms of heartburn and regurgitation; however, there was no evidence that one is better than the other. Five out of six studies reporting on intragastric pH provided the evidence of omeprazole’s superiority over lansoprazole in controlling gastric pH. Omeprazole lowered intragastric pH faster and the results lasted longer compared to lansoprazole. The results were statistically significant. Conclusion: There is no significant difference in the clinical effectiveness of omeprazole and lansoprazole in relieving symptoms of heartburn and regurgitation. However, omeprazole is more effective in reducing gastric acidity than lansoprazole.

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Skvortsova, T. A., G. Yu Knorring e E. N. Kareva. "Use of Omeprazole in Paediatric Patients in Russia". Doctor.Ru 20, n.º 10 (2021): 39–43. http://dx.doi.org/10.31550/1727-2378-2021-20-10-39-43.

Texto completo da fonte

Resumo:

Objective of the Review: To analyse clinical and pharmacological characteristics and normative documents in the use of modern proton pump inhibitors (PPI) in paediatric patients in the Russian Federation. Key Points. PPIs remain a widely used and efficient therapy of acid-related disorders in children; however, prescription should be based not only on clinical characteristics of a patient, but also on normative documents, e.g., instructions for the use of PPIs in paediatric population for certain indications approved by the Ministry of Health of Russia, since healthcare providers are responsible for off-label prescriptions. Conclusion. Omeprazole is one of the most well-studied PPIs; it has good evidence base for the use in children; however, in Russia, most omeprazoles have contraindications in paediatric population. Omez is indicated for the management of gastroesophageal reflux and duodenal ulcer caused by Helicobacter pylori in children. Keywords: acid-related disorders, children, paediatrics, proton pump inhibitors, Omeprazole.

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1382 (dezembro de 2011): 28. http://dx.doi.org/10.2165/00128415-201113820-00100.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1386 (janeiro de 2012): 29–30. http://dx.doi.org/10.2165/00128415-201213860-00102.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1390 (fevereiro de 2012): 28. http://dx.doi.org/10.2165/00128415-201213900-00108.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1391 (março de 2012): 32. http://dx.doi.org/10.2165/00128415-201213910-00116.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 703 (maio de 1998): 10. http://dx.doi.org/10.2165/00128415-199807030-00035.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 713 (agosto de 1998): 9. http://dx.doi.org/10.2165/00128415-199807130-00025.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 716 (agosto de 1998): 12. http://dx.doi.org/10.2165/00128415-199807160-00041.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 716 (agosto de 1998): 13. http://dx.doi.org/10.2165/00128415-199807160-00046.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 723 (outubro de 1998): 10. http://dx.doi.org/10.2165/00128415-199807230-00032.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 743 (março de 1999): 10–11. http://dx.doi.org/10.2165/00128415-199907430-00030.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 743 (março de 1999): 11. http://dx.doi.org/10.2165/00128415-199907430-00033.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 746 (abril de 1999): 9. http://dx.doi.org/10.2165/00128415-199907460-00028.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 751 (maio de 1999): 10. http://dx.doi.org/10.2165/00128415-199907510-00034.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 758 (julho de 1999): 10. http://dx.doi.org/10.2165/00128415-199907580-00032.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1194-1195 (março de 2008): 28. http://dx.doi.org/10.2165/00128415-200811940-00103.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1135 (janeiro de 2007): 24. http://dx.doi.org/10.2165/00128415-200711350-00095.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1136 (janeiro de 2007): 21. http://dx.doi.org/10.2165/00128415-200711360-00064.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1138 (fevereiro de 2007): 21. http://dx.doi.org/10.2165/00128415-200711380-00061.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1143 (março de 2007): 20. http://dx.doi.org/10.2165/00128415-200711430-00066.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1149 (abril de 2007): 19. http://dx.doi.org/10.2165/00128415-200711490-00060.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1153 (maio de 2007): 21. http://dx.doi.org/10.2165/00128415-200711530-00070.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1158 (junho de 2007): 22. http://dx.doi.org/10.2165/00128415-200711580-00061.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

&NA;. "Omeprazole". Inpharma Weekly &NA;, n.º 1203 (setembro de 1999): 16. http://dx.doi.org/10.2165/00128413-199912030-00026.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1359 (julho de 2011): 29. http://dx.doi.org/10.2165/00128415-201113590-00112.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1361 (julho de 2011): 31. http://dx.doi.org/10.2165/00128415-201113610-00112.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1361 (julho de 2011): 31. http://dx.doi.org/10.2165/00128415-201113610-00114.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 1366 (agosto de 2011): 23–24. http://dx.doi.org/10.2165/00128415-201113660-00089.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 532 (dezembro de 1994): 13. http://dx.doi.org/10.2165/00128415-199405320-00047.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 533 (janeiro de 1995): 9. http://dx.doi.org/10.2165/00128415-199505330-00033.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 538 (fevereiro de 1995): 12. http://dx.doi.org/10.2165/00128415-199505380-00049.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 540 (março de 1995): 10. http://dx.doi.org/10.2165/00128415-199505400-00033.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 547 (abril de 1995): 10. http://dx.doi.org/10.2165/00128415-199505470-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 551 (maio de 1995): 9. http://dx.doi.org/10.2165/00128415-199505510-00035.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 558 (julho de 1995): 10. http://dx.doi.org/10.2165/00128415-199505580-00029.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 560 (julho de 1995): 9. http://dx.doi.org/10.2165/00128415-199505600-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 564 (agosto de 1995): 10. http://dx.doi.org/10.2165/00128415-199505640-00027.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 566 (setembro de 1995): 10. http://dx.doi.org/10.2165/00128415-199505660-00038.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 567 (setembro de 1995): 9. http://dx.doi.org/10.2165/00128415-199505670-00031.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 567 (setembro de 1995): 10. http://dx.doi.org/10.2165/00128415-199505670-00033.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 585 (janeiro de 1996): 10. http://dx.doi.org/10.2165/00128415-199605850-00038.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 594 (março de 1996): 10. http://dx.doi.org/10.2165/00128415-199605940-00036.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 424 (outubro de 1992): 10. http://dx.doi.org/10.2165/00128415-199204240-00053.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

&NA;. "Omeprazole". Reactions Weekly &NA;, n.º 428 (novembro de 1992): 10. http://dx.doi.org/10.2165/00128415-199204280-00048.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!